August 29, 2020 | HealthClot

Common symptoms and presentations of Multiple Myeloma to primary care physicians

By HealthClot Moderator
August 29, 2020
0

Common symptoms and presentations of Multiple Myeloma to primary care physicians Presented By: Ola Landgren, M.D., Ph.D. – Professor of Medicine & Chief of Multiple Service at Memorial Sloan-Kettering in New York City Speaker Biography: Dr. Landgren is Professor of Medicine and Chief Attending Physician of the Myeloma Service at Memorial Sloan-Kettering Cancer Center (MSKCC) […]

Global Oncology/Cancer Drugs Market To Grow At CAGR of 7.6% During 2020 To 2028

By HealthClot Moderator
August 29, 2020
0

Global Oncology/Cancer Drugs Market To Grow At CAGR of 7.6% During 2020 To 2028 Pune, India, Aug. 29, 2020 (GLOBE NEWSWIRE) — The global oncology market is valued at USD 100.0 billion in 2020 and is anticipated to grow with a CAGR of 7.6% during the forecast period from 2020 to 2028. Increasing incidence of […]

Mangaluru: Cancer on worrisome rise in India: Dr Suresh Rao

By HealthClot Moderator
August 29, 2020
0

Mangaluru: Cancer on worrisome rise in India: Dr Suresh Rao Media Release Mangaluru, Aug 29: Recent reports from the Indian Council of Medical Research (ICMR) have indicated that in 2020 the country will have 13.9 lac afflicted with cancer and that tobacco-related cancer are expected to contribute to 3.7 lac (27.1%) of the total cancer […]

bluebird bio Presents New Results from Clinical Development Program of elivaldogene autotemcel …

By HealthClot Moderator
August 29, 2020
0

bluebird bio Presents New Results from Clinical Development Program of elivaldogene autotemcel … Article content continued About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment […]

By HealthClot Moderator
August 29, 2020
0

Ligand Pharmaceuticals (NASDAQ:LGND) Downgraded by BidaskClub to “Sell” Ligand Pharmaceuticals (NASDAQ:LGND) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday, BidAskClub reports. Several other brokerages have also recently weighed in on LGND. HC Wainwright reaffirmed a “buy” rating and […]